Mechanism of Action
Chondroitin's primary mechanism is inhibition of cartilage-degrading enzymes including matrix metalloproteinases and aggrecanases, which break down the proteoglycan matrix of cartilage in osteoarthritic joints. It also inhibits the synthesis of inflammatory mediators in chondrocytes and may stimulate the synthesis of hyaluronic acid, a component of synovial fluid. The combination of glucosamine and chondroitin is considered to have complementary mechanisms: glucosamine provides the building blocks for cartilage synthesis while chondroitin inhibits the enzymes that degrade it.
Evidence Summary
Chondroitin shares the mixed evidence profile of glucosamine. Some trials show benefit, others show limited effect over placebo. The GAIT trial in humans (2006, New England Journal of Medicine) found that the glucosamine-chondroitin combination showed significant benefit in a subgroup of patients with moderate to severe pain, though not in the overall study population. Veterinary-specific evidence is limited. A 2003 study by Moreau et al in dogs found improvement in force plate measurements with glucosamine-chondroitin supplementation. As with glucosamine, the honest position is that chondroitin is widely used in veterinary joint support protocols, is safe, and produces meaningful benefit in a proportion of patients.
In Petz Park Products
Hip and Joint for Dogs: Chondroitin 400mg per scoop. Hip and Joint for Cats: Chondroitin 120mg per scoop.
Safety and Considerations
Chondroitin is considered safe for long-term daily use in dogs and cats. It is derived from animal cartilage and is generally well tolerated. Animals with allergies to bovine or porcine products should be assessed by a veterinarian before use.